Format

Send to

Choose Destination
J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Author information

1
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
2
The University of Texas MD Anderson Cancer Center
3
Memorial Sloan Kettering Cancer Center
4
University of Alabama at Birmingham Comprehensive Cancer Center
5
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
6
Duke Cancer Institute
7
Yale Cancer Center/Smilow Cancer Hospital
8
Massachusetts General Hospital Cancer Center
9
Moffitt Cancer Center
10
Vanderbilt-Ingram Cancer Center
11
Stanford Cancer Institute
12
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
13
St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center
14
Mayo Clinic Cancer Center
15
Dana-Farber/Brigham and Women’s Cancer Center
16
Roswell Park Cancer Institute
17
Huntsman Cancer Institute at the University of Utah
18
University of Colorado Cancer Center
19
Fred & Pamela Buffett Cancer Center
20
City of Hope Comprehensive Cancer Center
21
UC San Diego Moores Cancer Center
22
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
23
Fox Chase Cancer Center
24
The Ohio State University Comprehensive Cancer Center–James Cancer Hospital and Solove Research Institute
25
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
26
University of Wisconsin Carbone Cancer Center
27
University of Michigan Comprehensive Cancer Center
28
UCSF Helen Diller Family Comprehensive Cancer Center
29
National Comprehensive Cancer Network

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers provide treatment recommendations for cancers of the lip, oral cavity, pharynx, larynx, ethmoid and maxillary sinuses, and salivary glands. Recommendations are also provided for occult primary of the head and neck (H&N), and separate algorithms have been developed by the panel for very advanced H&N cancers. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding the increase in human papillomavirus-associated oropharyngeal cancer and the availability of immunotherapy agents for treatment of patients with recurrent or metastatic H&N cancer.

PMID:
28596256
DOI:
10.6004/jnccn.2017.0101
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center